Statement 1 is not correct.
COVID-19 efficacy is moot as the risks outweigh the ad-hoc claims of benefits (see FDA EUA revocation below).
The use of HQC is now off-label as of June 15. As before, physicians can prescribe and FDA approved drug for use outside of its compliance scope.
The FDA Emergency Use Authorization revocation document states,
"
Recent results from a large randomized clinical trial in hospitalized patients, a population similar to the population for which chloroquine and hydroxychloroquine were authorized for emergency use, demonstrated that hydroxychloroquine showed no benefit on mortality or in speeding recovery. This outcome was consistent with other new data, including data showing that the suggested dosing regimens for chloroquine and hydroxychloroquine are unlikely to kill or inhibit the virus that causes COVID-19. The totality of scientific evidence currently available indicate a lack of benefit."
India and Turkey currently use HQC for COVID-19 patients. France, Belgium and Italy suspended HQC for COVID-19 patients in late May.
What about results? "
According to the government's own admission, only 22% of deaths in India are medically certified." There is no data to indicate whether or not HCQ has a positive impact on India's COVID-19 death rate.
FDA
Emergency Use Authorization revoked by FDA